Press release
Asia Pacific Type 2 Diabetes market is projected to reach USD 124.26 billion by 2033, Oral Anti-diabetics holds the highest market share | DataM Intelligence
Type 2 Diabetes
Growth drivers include rising diabetes prevalence, increasing demand for advanced therapies, and innovations by key market players.China, India, and several Southeast Asian countries are witnessing significant increases in type 2 diabetes incidence due to lifestyle changes and urbanization.
Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/type-2-diabetes-market?pratik
Type 2 Diabetes market 2025 Events
⇥ Abbott launched Ensure Diabetes Care, a clinically proven formula for blood sugar management, in India on November 13, 2025.
⇥ Abbott launched next-gen FreeStyle Libre 2 Plus CGM sensor for continuous glucose readings in India on August 21, 2025.
⇥ Dexcom announced Dexcom ONE+ CGM launch for type 2 diabetes in Australia, featuring adjustable alerts.
⇥ Insulet expanded Omnipod 5 automated insulin delivery system to Australia in March 2025.
⇥ Leading manufacturer launched advanced affordable insulin pen in India early 2025.
⇥ Asia Pacific diabetes market saw investments in digital health, CGM, and policy reforms for device coverage in 2025
Segmentation analysis
-►By Drug Class:
⇥ Oral Anti-diabetics: Dominant segment holding the highest market share, driven by preference for convenient, non-invasive first-line therapies like metformin, DPP-4 inhibitors, SGLT-2 inhibitors, and sulfonylureas in type 2 diabetes management.
⇥ Insulins: Significant share with steady demand for basal, bolus, and biosimilar options, particularly as disease progresses requiring glucose control beyond oral agents.
⇥ GLP-1 Receptor Agonists: Fastest-growing injectable segment due to benefits in glycemic control, weight management, and cardiovascular risk reduction, with high adoption in urbanizing APAC populations.
►By Route of Administration:
⇥ Oral: Leading category with maximum share, favored for ease of use, lower cost, and broad efficacy in early-stage type 2 diabetes treatment.
⇥ Subcutaneous: Growing rapidly for injectables like GLP-1s and insulins, supported by innovations in pens and pumps enhancing patient adherence.
⇥ Intravenous: Smaller share, used primarily in hospital settings for acute management.
"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=type-2-diabetes-market?pratik ((Purchase 2 or more Repots and get 50% Discount)
Regional insights:-
⇥ China leads as the largest national market in Asia Pacific, with its diabetes care drugs and devices sector valued at USD 8.98 billion in 2025 and expected to grow to USD 11.93 billion by 2030 at a CAGR of 5.85%. Key drivers include a massive diabetic population exceeding 140 million, expansions in tier-2/3 cities, national health directives for chronic disease coverage, and collaborations for affordable therapies.
⇥ India is poised for robust growth among Asia Pacific countries, with its diabetes market reaching USD 6.86 billion in 2024 and forecasted to hit USD 13.77 billion by 2035 at a CAGR of 6.54%. The surge is fueled by the second-highest global diabetes cases, unhealthy diets, sedentary habits, government healthcare investments, and rising demand for generics and digital management tools.
⇥ Japan, Australia, and South Korea represent other vital markets, with Japan dominating diabetes devices due to its aging population of over 11 million diabetics and strong public health policies covering insulin and monitoring. Trends emphasize precision tech, preventive care, and online pharmacies, while broader regional shifts focus on early screening and cost-effective innovations amid over 250 million Type 2 cases.
Key Players and Competitor Mentions:
⇥ Novo Nordisk - Recognized as a global leader in diabetes treatment with a strong presence across Asia Pacific, combining insulin, GLP-1 therapies and advanced delivery systems.
⇥ Sanofi - Offers a broad diabetes-care portfolio including insulins and oral antidiabetic drugs; has extensive regional distribution and strong regulatory/compliance capabilities.
⇥ Eli Lilly and Company - Focused on insulin analogs, next-gen formulations and combination therapies; increasingly active in fast-growing diabetes drug segments.
⇥ AstraZeneca - Key player for non-insulin diabetes drugs (e.g., SGLT-2 inhibitors or oral therapeutics), addressing growing demand for oral or non-injectable treatments.
⇥ Merck & Co., Inc. - Competes in oral antidiabetic medications and combination therapy segments, contributing to market depth and therapeutic variety.
⇥ Takeda Pharmaceutical Company - Especially relevant in certain Asia Pacific countries, leveraging regional footprint and local regulatory familiarity
Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/type-2-diabetes-market?pratik
key market Drivers:-
⇥ Rising Prevalence of Diabetes:
Rapid urbanization, sedentary lifestyles, and unhealthy diets are contributing to a sharp rise in Type 2 diabetes cases across India, China, Japan, and Southeast Asia.
⇥ Growing Obesity Rates:
Increasing obesity especially among younger populations is a major driver of insulin resistance and diabetes incidence.
⇥ Aging Population:
Asia Pacific has one of the fastest-growing elderly populations, significantly increasing the demand for diabetes management therapies.
⇥ Improved Healthcare Access:
Expansion of hospital networks, better diagnostic facilities, and government-backed health programs are boosting treatment uptake.
⇥ Strong Adoption of Novel Therapies:
High demand for GLP-1 agonists, SGLT-2 inhibitors, and combination therapies is fueling market growth.
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asia Pacific Type 2 Diabetes market is projected to reach USD 124.26 billion by 2033, Oral Anti-diabetics holds the highest market share | DataM Intelligence here
News-ID: 4291303 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Application-Specific Integrated Circuit (ASIC) Market Set for Steady Growth to U …
The Global Application-Specific Integrated Circuit (ASIC) Market reached US$ 15.7 billion in 2022 and is expected to reach US$ 34.5 billion by 2030, growing with a CAGR of 8.3% during the forecast period 2023-2030. This sustained growth is driven by the explosive demand for high-performance, energy-efficient silicon for artificial intelligence (AI) inferencing, cryptocurrency mining, and advanced wireless communication (5G/6G), coupled with the increasing need for customized acceleration solutions across automotive,…
Asthma and COPD Drug Market to Witness Steady Growth, Fueled by Innovation and H …
The Global Asthma and COPD Drug Market is expected to grow at a CAGR of 3.9% during the forecast period (2024-2031). This steady growth is propelled by the persistently high and rising global prevalence of chronic respiratory diseases, continuous innovation in biologic therapies and smart inhaler technologies, and the expanding aging population more susceptible to COPD, driving long-term treatment demand.
Get a Free Sample PDF Of This Report (Get Higher Priority…
Ambulatory Blood Pressure Monitors Market Set for Strong Growth to USD 3.42 Bill …
The Global Ambulatory Blood Pressure Monitors (ABPM) Market reached US$ 1.33 billion in 2024 and is expected to reach US$ 3.42 billion by 2033, growing at a CAGR of 11.2% during the forecast period 2025-2033. This robust growth is propelled by the rising global prevalence of hypertension, the increasing clinical preference for 24-hour ABPM over clinic readings for accurate diagnosis and treatment monitoring, and technological advancements that enhance device connectivity…
Advanced Wound Care Market Poised for Steady Growth, Driven by Rising Chronic Wo …
The Global Advanced Wound Care Market was valued at USD 10,318.90 million in 2021 and is forecast to grow at a CAGR of 4.90% during the forecast period (2024-2031). This steady growth is fueled by the increasing global prevalence of chronic wounds, such as diabetic foot ulcers and venous leg ulcers, the aging global population, and continuous advancements in wound therapy technologies that improve healing times and patient outcomes.
Get a…
More Releases for Asia
Asia Private Equity Firm, Asia Private Equity Management, Asia Private Equity Se …
The private equity market in China has been rapidly growing in recent years. Private equity (PE) refers to the purchase of shares in a company that are not publicly traded on a stock exchange. PE firms typically target companies that are undervalued or in need of capital for growth, and aim to improve the company's operations and financial performance before selling it at a higher value.
https://boomingfaucet.com/
Asia Private Equity Consulting
E-mail:nolan@pandacuads.com
In China,…
South East Asia Business Jet Market And Top Key Players are Asia Corporate Jet, …
By 2022, the South East Asia Business Jet Markets estimated to reach US$ XX Mn, up from US$ XX Mn in 2016, growing at a CAGR of XX% during the forecast period. The Global Business Jet Market, currently at 21 million USD, contributes the highest share in the market and is poised to grow at the fastest rate in the future. The three broad categories of business jets are Small,…
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022.
23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property…
PEOPLEWAVE WINS ASIA TECH PODCAST PITCHDECK ASIA 2019 AWARDS
15 January 2019, Singapore – Peoplewave, Asia’s leading data-driven HR technology company, won the Asia Tech Podcast (ATP) Pitchdeck Asia 2019 Awards, being awarded “Startup Most Likely to Succeed in 2019".
The 2019 Pitchdeck Asia Awards is an opportunity for the Asian Startup Ecosystem to shine a spotlight on some of its best startups. The awards were decided by a public vote. More than 7,200 votes were cast by registered LinkedIn…
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia
Equipping Asia’s navies with the latest diving technology for asymmetric warfare and
operations
SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is
seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting…
Asia Diligence – Specialist Investigative Due Diligence for Asia & Beyond
Asia Diligence today announced the opening of its European Customer Services office in the United Kingdom. The office is to be managed by Steve Fowler and will focus on providing services to Asia Diligence’s European customers. Asia Diligence is also planning to open a US office in the near future, which will provide customer service to its US and North American clients.
Asked to comment on the move, Luke Palmer, the…
